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The majority of patients with type 2 diabetes do not reach target levels of glycated haemoglobin
(HbA1c < 7%). We investigated the prevalence of HbA1c-target achievement and opportunities
afforded by lifestyle and pharmacological treatment to increase target achievement. We per-
formed cross-sectional analyses of baseline data from the Diabetes and Lifestyle Cohort
Twente-1 (DIALECT-1). Patients were divided according to (1) HbA1c <53 and ≥53 mmol/mol
(<7%) and (2) non-insulin treatment and tertiles of daily insulin use. We found that 161 (36%)
patients achieved the target HbA1c level. Patients with HbA1c ≥53 mmol/mol had a longer
duration of diabetes (13 [8-20] vs 9 [4-14] years; P < .001) and more frequently were insulin-
users (76% vs 41%, P < .001). Patients in the highest tertile of insulin use had a higher body
mass index than those in the lowest tertile (35.8  5.5 vs 29.8  5.5 kg/m2; P < .001). Achieve-
ment of target HbA1c is low in this type 2 diabetes population. High resistance to pharmacolog-
ical treatment, paralleled with high body mass index, illustrates that increasing insulin sensitivity
through lifestyle intervention is the best opportunity to improve HbA1c target achievement in
this real-life population.
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1 | INTRODUCTION
Tight glycaemic control in type 2 diabetes mellitus reduces the risk of
microvascular complications and, to a lesser extent, of cardiovascular
disease also. Each 1% of mean HbA1c reduction has been associated
with a 21% reduction in risk of any diabetes-related complication.1 In
general, a target HbA1c level of <53 mmol/mol (<7%) is optimal,
according to diabetes guidelines.2
However, a recent meta-analysis demonstrated that HbA1c target
achievement is low, with a pooled average of 43% worldwide,3 both
in primary and secondary care settings. The reason for this low target
achievement, despite the expanding arsenal of glucose-lowering
interventions, remains to be elucidated. Although both lifestyle and
pharmacological management contribute to glycaemic control, few
studies address both aspects of treatment in relation to HbA1c target
achievement.
In this study we aim to (1) investigate the prevalence of ideal
HbA1c target achievement in a real-life population of type 2 diabetes
patients in secondary health care, and (2) identify opportunities for
improving ideal HbA1c target achievement, using an integrated
assessment of lifestyle factors and pharmacological treatment.
2 | MATERIALS AND METHODS
This was a cross-sectional study using baseline data from the Diabetes
and Lifestyle Cohort Twente-1 (DIALECT-1). DIALECT-1 was†These authors contributed equally
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performed in the outpatient clinic of the Ziekenhuisgroep Twente
(ZGT) hospital, Almelo and Hengelo, The Netherlands. The study pop-
ulation and study procedures have been described previously.4 In
brief, 450 patients with type 2 diabetes, aged 18+ years were included
and exclusion criteria were renal replacement therapy or inability to
understand the concept of informed consent. The ZGT hospital is a
secondary health care centre for diabetes treatment. In The Nether-
lands, criteria for referral from primary to secondary health care are
inability to achieve adequate glycaemic control with oral antidiabetic
drugs or a standard insulin regimen, macroalbuminuria and/or esti-
mated glomerular filtration rate (eGFR) ≤ 60 mL/min or multiple car-
diovascular complications. The study has been approved by local
institutional review boards (METC-Twente, NL57219.044.16; METC-
Groningen, 1009.68020), is registered in The Netherlands Trial Regis-
ter (NTR trial code 5855) and was performed according to the Guide-
lines of Good Clinical Practice and the Declaration of Helsinki.
2.1 | Variables
Sociodemographic characteristics and medical history of participants, as
well as current medications, were recorded and anthropometric dimen-
sions were measured using standard procedures. Physical activity was
assessed using the previously validated Short Questionnaire to Assess
Health-Enhancing Physical Activity (SQUASH).5 Diet was assessed
using a semi-quantitative validated food-frequency questionnaire (FFQ)
that was developed and validated at the Wageningen University, inquir-
ing about intake of 177 items during the last month, taking seasonal
variations into account.6 Both questionnaires were self-administered
and completed at home, and subsequently checked for completeness
by a trained researcher. Dietary data were converted into daily nutrient
intake of macronutrients (ie, carbohydrates, protein, fat) using the
Dutch Food Composition Table of 2013. Intake of food groups
included in the Dutch Healthy Diet guidelines (DHD) was calculated by
summing up daily intake across all food items in that category
(Table S1).7 In addition, specific carbohydrate intake from several differ-
ent carbohydrate-rich food categories was calculated by summing up
carbohydrate content across all food items in that category (Table S2).
Blood was drawn from venipuncture in a non-fasting state, for
measurement of HbA1c and other variables relevant to diabetes.
HbA1c was measured by the Roche Tina-quant 3rd generation immu-
noturbidimetric method, standardized according to International Fed-
eration of Clinical Chemistry and Laboratory Medicine, on a Clinical
Chemistry Analyzer and Immunochemistry Analyzer (COBAS 6000,
Roche Diagnostics GmbH, Mannheim, Germany). Data on dietary
sodium intake were derived from 24-hour urinary sodium excretion.
2.2 | Targets and definitions
Ideal HbA1c was set as <53 mmol/mol (<7%), according to the
European guidelines for management in type 2 diabetes mellitus,
which have been adopted for use in The Netherlands. Lifestyle recom-
mendations were maintenance of body mass index (BMI) ≤ 25 kg/m2,
smoking cessation and physical activity (30 minutes of moderate-
vigorous exercise) at least 5 days per week.8 Dietary recommenda-
tions were derived from the DHD Guidelines 2015, published by the
Health Council of The Netherlands.7 In brief, recommended intakes
were: vegetables, ≥200 g/d; fruits, ≥200 g/d; legumes, ≥1 portion/
wk; nuts, ≥ 15 g/d; low-fat dairy, 2 to 3 portions/d; fish, ≥1 portion/
wk; tea, ≥3 cups/d; red meat, ≤45 g/d; alcohol, ≤10 g/d; sodium,
≤2.3 g/d; and no hard margarines, cooking fats, processed meat,
sweetened beverages or fruit juices. Adherence to these lifestyle
guidelines was determined as described previously.9
2.3 | Statistics
All statistical analyses were performed using SPSS version 23.0 (IBM,
Chicago, Illinois). Normality of data was assessed by visual inspection of
frequency histograms. Normally distributed variables were presented
as mean  standard deviation, skewed variables as median (interquar-
tile range) and dichotomous variables as numbers (percentage).
Patients were divided according to HbA1c at ideal target (HbA1c-
OIT; <53 mmol/mol; <7%) and HbA1c not at ideal target (HbA1c-
NOIT; ≥53 mmol/mol; ≥7%). Differences between groups were tested
using students t-test (normal distribution), Mann-Whitney U (skewed
distribution) and Chi-Square (categorical).
As we found that intensity of blood glucose-lowering treatment
was higher in patients with HbA1c-NOIT, we aimed to determine
which factors were associated with a higher intensity of treatment.
We divided patients into four groups; the first group was comprised
of non-insulin users (ie, only non-insulin blood glucose-lowering treat-
ment) and the second, third and fourth groups were based on tertiles
of insulin units used per day, as currently no cut-off point to grade
intensity of insulin treatment exists. Differences among groups were
tested using one-way ANOVA (normal distribution), Kruskal-Wallis
(skewed distribution) and Chi-Square.
3 | RESULTS
HbA1c data were available for all of the 450 patients included in
DIALECT-1. Baseline characteristics are shown in Table 1. Mean age
was 63  9 years, and 58% (n = 261) of the patients were men. The
median duration of type 2 diabetes was 11 [7-18] years. Type 2 diabe-
tes-related complications were highly prevalent: 296 (67%) patients
had microvascular disease and 160 (36%) had macrovascular disease.
Mean HbA1c in our population was 57 12 mmol/mol
(7.4% 3.2%). In total, 161 patients (36%) achieved an HbA1c-OIT, of
which 33 patients (7% of total population) achieved an HbA1c < 42
mmol/mol (<6%). Patients with HbA1c-NOIT had a longer median
duration of type 2 diabetes than those with HbA1c-OIT (13 [8-20] vs
9 [4-14] years, P < .001).
Among the total population, 37% of patients were non-insulin
users. In this group, patients with HbA1c-NOIT used more non-insulin
blood glucose-lowering drugs per day than patients with HbA1c-OIT
(45% vs 18% used 3-4 drugs/d; P < .001). The remaining 63% of
patients used insulin, and insulin use was substantially higher in those
with HbA1c-NOIT (76%) than in those with HbA1c-OIT (41%);
(P < .001) (Table 1). Although there were no differences in insulin regi-
mens between the ideal HbA1c target groups, the amount of total daily
units of insulin was significantly higher in those with HbA1c-NOIT than
in those with HbA1c-OIT (86  54 vs 70  42 units/d; P = .02).
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TABLE 1 Patient characteristics of DIALECT-1 by a breakup of ideal HbA1c target achievement
Variable Total population
HbA1c-OIT HbA1c-NOIT
P valuen <53 mmol/mol ≥ 53 mmol/mol
Number of patients, n (%) n = 450 n = 161 (36) n = 287 (64)
Age, y 450 63  9 63  9 63  9 .63
Men, n (%) 450 261 (58) 85 (53) 174 (61) .13
Diabetes duration, y 450 11 [7-18] 9 [4-14] 13 [8-20] <.001
Body mass index, kg/m2 448 32.9  6.2 33.0  6.8 32.8  5.8 .80
Waist/hip ratio, cm/cm 441 1.00  0.09 0.99  0.08 1.01  0.09 .09
Systolic blood pressure, mm Hg 449 136  16 135  17 137  16 .25
Diastolic blood pressure, mm Hg 448 74  10 74  10 75  9 .53
Heart frequency, beats/min 444 74  13 74  14 74  12 .98
Blood pressure on target, n (%) 449 239 (53) 95 (58) 144 (50) .11
LDL cholesterol ≤2.5 mmol/L, n (%) 428 334 (78) 127 (80) 207 (77) .53
Serum HbA1c, mmol/mol 450 57  12 46  5 64  10 <.001
Serum HbA1c, % 450 7.4  3.2 6.4  2.6 8.0  3.1 <.001
Glycosuria, g/24 h 361 0.5 [0.1-5.5] 0.1 [0.0-0.4] 2.0 [0.2-9.0] <.001
Co-morbidity
Microvascular disease, n (%) 444 296 (67) 104 (65) 192 (68) .46
Nephropathy, n (%) 446 189 (42) 77 (48) 112 (39) .08
eGFR <60, n (%) 450 104 (23) 49 (30) 55 (19) .008
Albuminuria, n (%) 445 136 (31) 48 (30) 88 (31) .85
Retinopathy, n (%) 447 108 (25) 26 (16) 84 (30) .002
Neuropathy, n (%) 450 162 (36) 57 (35) 105 (37) .73
Macrovascular disease, n (%) 450 160 (36) 64 (39) 96 (33) .22
Coronary artery disease, n (%) 450 100 (22) 37 (23) 63 (22) .85
Cerebrovascular disease, n (%) 450 49 (11) 20 (12) 29 (10) .48
Peripheral artery disease, n (%) 450 40 (9) 18 (11) 22 (8) .23
Pharmacological management
Metformin, n (%) 450 333 (74) 120 (74) 213 (74) .89
Sulfonylureas, n (%) 450 114 (25) 42 (26) 72 (25) .87
DPP-4 inhibitors, n (%) 450 19 (4) 8 (5) 11 (4) .59
GLP-1 analogues, n (%) 450 45 (10) 17 (10) 28 (10) .82
SGLT-2 inhibitors, n (%) 450 4 (1) 0 (0) 4 (1) .13
Non-insulin users, n (%) 450 165 (37) 97 (60) 68 (24)
Number of used non-insulin agents 165 <.001
0, n (% of non-insulin users) 165 19 (12) 17 (18) 2 (3)
1, n (% of non-insulin users) 165 57 (35) 40 (41) 17 (25)
2, n (% of non-insulin users) 165 41 (25) 22 (23) 19 (28)
3, n (% of non-insulin users) 165 18 (11) 6 (6) 12 (18)
4, n (% of non-insulin users) 165 30 (18) 12 (12) 18 (27)
Insulin users, n (%) 450 285 (63) 66 (41) 219 (76) <.001
Basal regimen, n (% of insulin users) 285 36 (13) 9 (14) 27 (12) .65
Basal bolus/plus regimen, n (% of insulin users) 285 160 (56) 39 (59) 121 (55)
Mixed regimen, n (% of insulin users) 285 60 (21) 14 (21) 46 (21)
Bolus only regimen, n (% of insulin users) 285 29 (10) 4 (6) 25 (11)
Total daily units of insulin, units/d 285 82  52 70  42 86  54 .02
Total daily units of insulin per kg
body weight, units/kg
285 0.83  0.48 0.73  0.39 0.88  0.50 .04
Dietary intake
Total energy intake, kcal/d 439 1910  644 1845  617 1947  658 .12
Intake of fibers, g/d 439 21  7 20  7 21  7 .22
Intake of carbohydrates, g/d 439 206  71 200  68 209  72 .20
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In general, adherence to DHD guidelines was low, and was simi-
lar, for the most part, between groups (Table 1). Patients with HbA1c-
NOIT less often adhered to the guideline concerning dietary salt
intake than those with HbA1c-OIT (8% vs 19%; P = .001).
When considering the factors associated with higher intensity of
blood glucose-lowering treatment (Table 2), we found that HbA1c
was higher in each group of higher intensity treatment (P < .001);
thus, ideal HbA1c target achievement was lower per group (P < .001).
Body mass index was higher in every higher tertile of daily use of insu-
lin: tertile 1, 29.8  5.5 kg/m2; tertile 2, 31.9  4.8 kg/m2; tertile
3, 35.8  5.5 kg/m2 (P < .001). Total carbohydrate intake was higher
in insulin users as compared to non-insulin users (207 [168-256] vs
189 [149-234] g/d; P = .03), while protein and fat intake were not
statistically different between the groups (P = .09 and P = .20, respec-
tively). Regarding dietary source of carbohydrate, carbohydrate intake
from bread, potatoes, dairy and fruit was higher in insulin users than
in non-insulin users (Figure S1). Adherence to DHD guidelines was
similar, for the most part, among all four groups (data not shown).
4 | DISCUSSION
We studied the prevalence of ideal HbA1c target achievement in a
real-world setting of treatment for type 2 diabetes mellitus, and aimed
to pinpoint opportunities for improving target achievement. In this
secondary care setting, the ideal target of <53 mmol/mol (<7%) was
not reached in two-thirds of patients (64%), which is somewhat higher
than the reported worldwide pooled-average (57%).3 The latter report,
however, also included less complicated type 2 diabetes mellitus
populations. In our population, median diabetes duration was
11 years, and those with HbA1c-NOIT had a longer duration of diabe-
tes than those with HbA1c-OIT (median, 13 vs 8 years). Evaluation of
pharmacological treatment showed a high degree of treatment resis-
tance, as patients who did not achieve the target more frequently
used insulin (76%), using a quite high average daily dose of insulin
(86 units/d). Furthermore, higher daily insulin dosage was paralleled
by higher BMI. Therefore, the overall picture in those with HbA1c-
NOIT is that of a group using high intensity blood glucose-lowering
treatment that is caught in a vicious circle of increased insulin resis-
tance, insulin use and obesity.
Along with treatment resistance, other factors could also play a
role in low ideal target achievement. Submaximal pharmacological
treatment was present in 57% of HbA1c-NOIT patients, as 24% were
not currently using insulin treatment, and 12% and 21%, respectively,
were using a basal or mixed insulin regimen. The decision to not initi-
ate a basal bolus/plus insulin regimen in some patients may have been
under delibarate consideration, and may be based, for example, on
patient preference or the inability to self-monitor blood glucose levels.
In addition, treatment adherence should be addressed. Reports have
TABLE 1 (Continued)
Variable Total population
HbA1c-OIT HbA1c-NOIT
P valuen <53 mmol/mol ≥ 53 mmol/mol
Carbohydrate intake from food groups
Bread, g carbohydrates/d 439 59 [42-73] 53 [41-72] 61 [43-75] .19
Snacks, g carbohydrates/d 439 24 [12-37] 21 [9-34] 26 [14-37] .03
Potatoes, g carbohydrates/d 439 20 [12-30] 20 [12-31] 20 [12-30] .93
Dairy, g carbohydrates/d 439 19 [12-29] 19 [11-28] 19 [13-29] .51
Fruit, g carbohydrates/d 439 19 [10-29] 16 [9-27] 21 [11-31] .12
Rice/pasta/dough, g carbohydrates/d 439 8 [4-14] 7 [3-12] 8 [4-15] .09
Lifestyle guideline adherence
BMI ≤25 kg/m2, n (%) 448 24 (5) 8 (5) 16 (6) .75
Current smokers, n (%) 450 75 (17) 31 (19) 44 (15) .29
Physical activity, n (%) 433 253 (58) 96 (60) 157 (57) .53
Vegetable intake, n (%) 440 31 (7) 11 (7) 20 (7) .92
Fruit intake, n (%) 440 122 (28) 44 (28) 78 (28) .94
Legume intake, n (%) 440 257 (58) 88 (55) 169 (60) .27
Nuts intake, n (%) 440 61 (14) 13 (8) 48 (17) .008
Fish intake, n (%) 440 161 (37) 56 (35) 105 (38) .60
Fats and oils intake, n (%) 440 286 (65) 112 (70) 174 (62) .10
Dairy intake, n (%) 440 88 (20) 29 (18) 59 (21) .46
Red meat intake, n (%) 440 54 (12) 20 (13) 34 (12) .91
Processed meat intake, n (%) 440 8 (2) 3 (2) 5 (2) .95
Tea intake, n (%) 440 36 (8) 17 (11) 19 (7) .16
Sweet beverages intake, n (%) 440 150 (34) 54 (34) 96 (34) .91
Alcohol intake, n (%) 438 310 (71) 113 (71) 197 (71) .92
Salt intake, n (%) 443 53 (12) 30 (19) 23 (8) .001
Abbreviations: DPP4, Dipeptidylpeptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, Glucagon-like peptide-1, SGLT-2, Sodium-glucose
co-transporter-2; HbA1c, glycated haemoglobin; NOIT, not on ideal target; OIT, on ideal target.
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found adherence rates of 20%-50% for specific blood glucose-
lowering drug classes in type 2 diabetes patients, and low adherence
has been associated with decreased HbA1c target achievement, along
with worse clinical outcomes.10
As a probable explanation for therapy resistance, adherence to
lifestyle guidelines was rather low in the studied population. Different
meta-analyses have demonstrated that adopting a healthy diet and
increasing physical activity can significantly reduce HbA1c and fasting
glucose and improve insulin sensitivity.11 Notably, weight loss can
lead to remission in type 2 diabetes, and also in patients who are
already using insulin.12
The main strengths of this study are the real-world data and the
integrated analysis of both lifestyle and pharmacological management.
A limitation of this study is a possible reverse causality bias as the result
of the cross-sectional setting. In addition, the use of the FFQ to assess
diet might lead to underestimation of the intake of unhealthy products
in this obese population.13 Nevertheless, there are currently no better
methods for registration of dietary habits in a study of this size.
The question of how ideal HbA1c target achievement can be
improved in clinical practice arises. In our opinion, given the apparent
resistance to insulin treatment, the aim should be to improve insulin
sensitivity, ideally by lifestyle intervention. The high degree of obesity,
and the low degree of adherence to DHD guidelines signal important
opportunities for lifestyle intervention. Intensifying pharmacological
therapy may also improve glycaemic control. Once-daily insulin users
could expand to a basal bolus/plus regimen: however, increasing insulin
use is associated with weight gain and may fuel the vicious circle of
insulin resistance. Moreover, increasing the dose of insulin appears to
have limited efficacy; 17% of our population did not achieve the ideal
HbA1c target despite 91+ units of insulin/d. In our opinion, pharmaco-
logical therapy should be applied to support lifestyle intervention and
should aim to facilitate increasing insulin sensitivity. As important
options, glucagon-like peptide-1 (GLP-1) analogues and sodium-glucose
co-transporter-2 (SGLT-2) inhibitors could be valuable, as they lower
HbA1c along with a decrease in body weight and in long-term cardio-
vascular risk without increased risk of hypoglycaemia.14,15
In conclusion, ideal HbA1c target achievement was low in this real-
life population of type 2 diabetes patients under treatment in secondary
care, apparently because of resistance to pharmacological treatment,
paralleled by high BMI. Therefore, treatment should be aimed at
increasing insulin sensitivity through lifestyle interventions such as
reducing weight, increasing physical activity and adopting a healthy diet.
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TABLE 2 Patient characteristics by a breakup of blood glucose-lowering treatment intensity
Variables No insulin Insulin tertile 1 Insulin tertile 2 Insulin tertile 3 P value
Insulin use, IE min-max — 7-54 56-90 91-328
Number of patients, n (% of total population) 166 (37) 93 (21) 96 (21) 95 (21)
Total daily units of insulin, units/d — 38 [28-44] 70 [62-78] 124 [106-163] <.001
Total daily units of insulin per kg body
weight, units/kg
— 0.41  0.15 0.78  0.16 1.31  0.50 <.001
Age, y 62  9 63  9 64  9 63  8 .25
Men, n (%) 93 (56) 56 (60) 47 (49) 65 (68) .05
Diabetes duration, y 7 [3-12] 11 [7-17] 15 [10-23] 15 [11-20] <.001
Serum HbA1c, mmol/mol 52  10 59  12 60  11 62  11 <.001
Serum HbA1c, % 6.9  3.1 7.5  3.2 7.6  3.2 7.8  3.2 <.001
HbA1c < 53 mmol/mol, n (%) 97 (58) 26 (28) 22 (23) 16 (17) <.001
Microvascular disease, n (%) 90 (55) 61 (67) 67 (70) 78 (83) <.001
Macrovascular disease, n (%) 55 (33) 31 (33) 31 (32) 43 (45) .17
BMI, kg/m2 33.5  6.8 29.8  5.5 31.9  4.8 35.8  5.5 <.001
Waist/hip ratio 1.00  0.09 0.98  0.09 0.99  0.08 1.04  0.10 <.001
Adherent to guideline physical activity, n (%) 91 (57) 58 (63) 48 (63) 46 (50) .11
Dietary intake
Total energy intake, kilocalories/d 1762 [1388-2176] 1859 [1476-2293] 1886 [1520-2318] 1969 [1548-2334] .12
Urinary sodium excretion, mmol/d 178  78 178  75 177  73 218  87 <.001
Urinary potassium excretion, mmol/d 74  24 80  27 77  26 82  25 .07
Sodium-to-potassium ratio, mmol/mmol 2.51  0.99 2.34  0.90 2.39  0.87 2.77  1.14 .01
Intake of protein, g/d 73 [59-89] 76 [67-91] 77 [65-92] 80 [67-97] .09
Intake of fat, g/d 71 [49-91] 73 [50-90] 73 [59-93] 78 [60-106] .20
Intake of carbohydrates, g/d 191 [150-234] 206 [155-243] 208 [169-269] 205 [174-260] .03
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; IE, insulin units.
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